ArticleDrug design, development and therapy2025

Effectiveness and Safety of Anlotinib-Related Therapeutic Regimens in Patients with Previously Immune Checkpoint Inhibitors-Treated Advanced NSCLC: A Real-World Exploratory Study.

Xue-Sen Fang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.